MAP2K1 and pancreatic ductal adenocarcinoma: It has been found that a specific inhibition of MEK1/2 kinase activity, associated with a decrease in phospho-ERK, enhanced the effects of nab-paclitaxel-based chemotherapy in pancreatic ductal adenocarcinoma patients (33).